<?xml version="1.0" encoding="UTF-8"?>
<p>Moving beyond early systemic therapy escalation, there has been an increased focus on the role of local cytoreductive and metastasis-directed interventions (primarily stereotactic ablative body radiotherapy (SABR)) to gain additional oncological benefit.
 <xref rid="R2" ref-type="bibr">2</xref> This is in part based on the emergence of the ‘oligo-metastatic state’, which may exhibit different biological characteristics to poly-metastatic prostate cancer.
 <xref rid="R10" ref-type="bibr">10</xref>
</p>
